NTRA Natera, Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 1604821 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY37.4%
TTM net income YoY46.7%
TTM EPS YoY51.1%
Revenue 3-yr CAGR43.3%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-9.0%
Net margin-5.7%
FCF margin1.8%
EBITDA margin-7.1%
Returns
ROE-10.6%
ROA-7.2%
ROIC (approx.)-41.9%
Asset turnover1.27x
Leverage & solvency
Liabilities / assets32.0%
Debt / equity0.00x
Current ratio2.81x
Interest coverage-70.84x
Cash quality & payout
Operating cash flow / net income-1.29x
Accruals ratio-16.5%
Payout ratio—
Capex / revenue5.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2.31B | $1.70B | $1.08B | $820.22M | $625.49M |
| R&D expense | $624.11M | $404.14M | $320.68M | $316.42M | $264.21M |
| SG&A expense | $1.18B | $841.31M | $618.31M | $588.59M | $511.03M |
| Operating income | -$309.91M | -$222.29M | -$446.25M | -$541.04M | -$468.17M |
| Interest expense | $4.07M | $10.69M | $12.64M | $9.32M | $8.30M |
| Pretax income | -$268.09M | -$189.73M | -$434.53M | -$546.82M | -$471.10M |
| Income tax | -$59.93M | $695,000 | $271,000 | $978,000 | $618,000 |
| Net income | -$208.16M | -$190.43M | -$434.80M | -$547.80M | -$471.72M |
| EBITDA | -$268.15M | -$191.33M | -$422.15M | -$524.34M | -$456.92M |
| EPS (basic) | -1.52 | -1.53 | -3.78 | -5.57 | -5.21 |
| EPS (diluted) | -1.52 | -1.53 | -3.78 | -5.57 | -5.21 |
| Weighted avg. shares (diluted) | 136.72M | 124.72M | 115.00M | 98.41M | 90.56M |
| Banking | |||||
| Provision for credit losses | — | — | — | — | $156,000 |
| Balance sheet | |||||
| Cash & equivalents | $1.08B | $945.59M | $642.10M | $466.09M | $84.61M |
| Short-term investments | — | $22.69M | $236.88M | $432.30M | $829.90M |
| Receivables | $296.53M | $314.17M | $278.29M | $244.38M | $122.07M |
| Inventory | $68.44M | $44.74M | $40.76M | $35.41M | $26.91M |
| Current assets | $1.50B | $1.38B | $1.26B | $1.21B | $1.09B |
| PP&E, net | $241.18M | $162.05M | $111.21M | $92.45M | $65.52M |
| Goodwill | $141.07M | — | — | — | — |
| Intangibles | $373.71M | $10.93M | — | — | — |
| Total assets | $2.40B | $1.66B | $1.44B | $1.39B | $1.24B |
| Current liabilities | $441.23M | $344.05M | $307.27M | $310.50M | $218.96M |
| Short-term debt | $80.32M | $80.36M | $80.40M | $80.35M | $50.05M |
| Long-term debt | — | — | $282.94M | $281.65M | $280.39M |
| Total debt | — | — | $363.35M | $362.00M | $330.45M |
| Total liabilities | $685.93M | $465.31M | $676.37M | $688.73M | $583.18M |
| Shareholders' equity | $1.71B | $1.20B | $765.33M | $705.74M | $653.30M |
| Net debt | — | — | -$278.75M | -$104.09M | $245.83M |
| Shares outstanding | 139.69M | 132.65M | 119.58M | 111.25M | 95.14M |
| Cash flow statement | |||||
| Operating cash flow | $215.30M | $135.66M | -$246.96M | -$431.50M | -$335.24M |
| Capital expenditure | $106.19M | $66.42M | $39.20M | $47.70M | $41.03M |
| Free cash flow | $109.11M | $69.24M | -$286.15M | -$479.20M | -$376.27M |
| Investing cash flow | -$132.21M | $137.62M | $168.50M | $330.34M | -$205.19M |
| Financing cash flow | $47.46M | $30.20M | $254.46M | $482.64M | $576.19M |
| Depreciation & amortization | $41.76M | $30.97M | $24.10M | $16.70M | $11.25M |
| Stock-based compensation | $354.40M | $274.43M | $191.81M | $152.38M | $115.22M |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.